Xtalks Life Science Webinars

This strategy focuses on Phases I and II, aiming to achieve proof-of-concept as efficiently as possible, completing all learning required to plan a comprehensive and effective Phase III program.

TORONTO (PRWEB)
July 18, 2023

Bringing new hope to the field of small pharma, a webinar addressing a novel service paradigm for efficient Phase I and II trials is set to take place. The event will provide a fresh perspective on how small pharma, including emerging, virtual and small biotechnology companies, can navigate the complexities of early clinical development.

These organizations often find themselves navigating a fragmented vendor network and relying on multiple contract development and manufacturing organizations (CDMOs). This approach, however, often lacks the comprehensive expertise and strategic planning required to efficiently address the intricacies of early clinical development.

The upcoming webinar will introduce a new concept — intelligent drug development. This strategy focuses on Phases I and II, aiming to achieve proof-of-concept as efficiently as possible, completing all learning required to plan a comprehensive and effective Phase III program. The model allows small pharma access to a multi-disciplinary team that builds and drives a strategic plan, enhancing scientific knowledge and ensuring maximum flexibility, coordination and speed.

The strategic team will guide small pharma sponsors in building the strategic plan, selecting and coordinating partners from the fragmented vendor space and interpreting emerging clinical data to lay the foundations for the next stages of clinical and drug product development.

Leading the discussion for the PPD clinical research business of Thermo Fisher Scientific will be experts from the Strategic Development Consulting team, Gary M. Klaich, PhD, Senior Nonclinical Strategy Director, and Kevin M. Kane, PhD, CMC Strategy Director.

The PPD, clinical research business, is renowned for its commitment to accelerating innovation and increasing drug development productivity. The business covers multiple therapeutic areas and includes early development, all phases of clinical development, peri- and post-approval strategies and comprehensive laboratory services.

The collaboration between the PPD clinical research business and Xtalks for this event represents a shared commitment to providing valuable insights and guidance to small pharma organizations, helping them navigate the intricacies of early clinical development.

The live webinar will take place on Thursday, July 27, 2023, at 10 am EDT (4 pm CEST/EU-Central). Don’t miss this opportunity to learn about the new intelligent drug development paradigm, designed to support small pharma in efficiently navigating early clinical development.

For more information, or to register for this event, visit Intelligent Drug Development: A New Service Paradigm for Small Pharma.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

SedMed’s Toilet Lift Assist

Woodbridge, Conn. (PRWEB)
July 18, 2023

SedMed, a mobility products company formed in 2020, today announced that its gas-spring-powered toilet lift is now available for preorder. The innovative, patent-pending product fits nearly all toilets, operates without electricity and securely mounts directly onto the toilet, supporting up to 80 percent of the user’s weight during the lift.

Sixty percent of injury-related emergencies are caused by falls, with 80 percent of them occurring in the bathroom. Many of these accidents often happen during transfers on and off the toilet. The risks of falls and injuries in the bathroom extend to caregivers as well, who selflessly dedicate themselves to the well-being of others. Over the past three years, SedMed has been continuously refining the product based on feedback from healthcare facilities, including assisted living and rehabilitation hospitals, to successfully align its mobility solution with the specific needs of the market.

“We are on a mission to prevent falls and injuries by delivering a secure and simple toileting experience,” said Jeremy Bronen, SedMed founder and CEO. “I am excited to have reached this important milestone for our company, backed by a team with an empathetic mindset and unwavering commitment to alleviating the anxieties and discomfort associated with toileting. By eliminating the risk of falls and injuries, SedMed is providing individuals with a renewed sense of safety and peace of mind.”

By empowering individuals with renewed independence, dignity and freedom, SedMed’s toilet lift is poised to make a significant impact on users’ lives, beyond the toilet. Feedback from healthcare workers and administrators has been overwhelmingly positive, highlighting the product’s potential benefits.

“We are always focused on the next best thing to improve the safety and wellness of our residents, so we were excited when SedMed offered us a pilot to try out the device,” said Rachel Little, RN, MSN, LNHA, Director of Clinical Compliance at Lutheran Senior Services (LSS). “The product has proven to be remarkable in its early stages, and in one case we had a resident who almost refused to give it back for further trialing because she loved it so much. We are excited to continue to work with SedMed to improve our residents’ lives.”

Motivated to assist a friend who suffered a stroke and struggled with daily activities such as toileting, Bronen founded SedMed as his senior design project at the University of Connecticut. Within three years, SedMed had transcended its origins as a design project boosted by robust financial support. The company has since secured over $1 million in funding, including $931,000 raised in a seed round, led by Connecticut Innovations, along with an additional $115,000 in grant funding from organizations like CTNext, FORGE, the Connecticut Center for Entrepreneurship and Innovation, UConn IQ, and the UConn School of Engineering.

In addition to the public launch of its core product, SedMed also unveiled a new website offering convenient preordering. The website also serves as a platform for healthcare facilities to explore options to elevate the perception of their facilities and is a valuable resource for older adults or people with disabilities.

For more information, please visit https://www.sed-med.com/

Share article on social media or email:

Gifting HeardThat is now available

VANCOUVER, British Columbia (PRWEB)
July 18, 2023

Singular Hearing, a subsidiary of Singular Software and creator of HeardThat, announced today the launch of a new gifting feature within the HeardThat app. The new feature makes it easy for loved ones to gift HeardThat to their parents, grandparents, or other friends or relatives who struggle to hear conversations in noisy environments like restaurants or social gatherings.

Family members are often the strongest influencers behind the adoption of hearing assistance devices for their relatives. The gifting feature expands the ways HeardThat reaches the people that need it. The purchaser can choose from three options:

• 
  3 months: $29.99
• 6 months: $53.99
• 1 year: $99.99

To buy HeardThat as a gift, simply download the app and go to the gift box icon in the upper left corner. Once purchased, HeardThat can be easily shared with the recipient via text or email.

“We know staying connected is one of the top motivators for adults 50+ to use technology,” said Singular Hearing CEO and HeardThat Founder Bruce Sharpe. “We’re thrilled to offer a new gifting feature that makes it easy for loved ones to help their family members stay connected. We believe that effortless conversations should be accessible to everyone, and our new feature is an important step towards achieving that goal.”

For more information on gifting HeardThat, please visit heardthat.ai/gifting.

About Singular Hearing

Singular Hearing is a subsidiary of Singular Software. Founder and CEO Bruce Sharpe and his team of AI experts have extensive experience in audio technology and a deep passion for finding effective solutions to everyday problems. They leverage machine learning and speech processing to create innovative products that help people live better by hearing better.

Singular Hearing is the creator of HeardThat, an award-winning innovative app that turns smartphones into sophisticated hearing-assistive devices. HeardThat helps those with hearing challenges by delivering clear speech in noisy environments.

HeardThat was named runner-up at the AGE-WELL National Impact Challenge 2022. The app also won the What’s Next Innovation Challenge Sponsored by AARP Innovation Labs at the 17th Annual What’s Next Longevity Venture Summit and was named the first runner-up in the What’s Next Business Plan Competition at the 17th What’s Next Longevity Venture Summit. For more information, please visit heardthat.ai.

###

Share article on social media or email:

LL&M is the meeting where interdisciplinary specialists convene to explore the controversial and complex world of blood cancer through debate, discussion, and networking.

MALVERN, Pa (PRWEB)
July 18, 2023

HMP Global, the leading omnichannel healthcare events and education company, today announced the International Myeloma Foundation (IMF) as a partner for the 2023 Lymphoma, Leukemia & Myeloma Congress (LL&M), the premier forum for industry-leading hematologic research and clinical case studies.

The 2023 LL&M Congress will be held October 18-21 at the Sheraton New York Times Square Hotel in New York City. LL&M is the meeting where interdisciplinary specialists convene to explore the controversial and complex world of blood cancer through debate, discussion, and networking. The educational program covers emerging data, innovative treatment methods, and emerging trends in lymphoma, myeloma, and leukemia disorders.

The International Myeloma Foundation is the first and largest global organization that focuses specifically on multiple myeloma, with more than 525,000 members in 140 countries. Through research, education, support, and advocacy, IMF works to find a cure for those living with multiple myeloma; provide educational seminars and workshops; provide support for patients around the world; and empower people to make a positive impact on issues critical to the myeloma community in the United States and globally.

“It is critical that like-minded organizations like IMF and LL&M work together to educate clinicians and develop strategies that improve patient care and outcomes,” said Dr. Joseph Mikhael, Chief Medical Officer of the IMF and professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. “Together we are advancing the science and research that will improve our patients’ lives while we work toward prevention and finding a cure.”

Educational Program

The LL&M Congress Chair is Morton Coleman, MD, and Co-Chairs include Richard R. Furman, MD; Jeremy Heinerich, PA-C; John P. Leonard, MD; Ruben Niesvizky, MD; and Gail J. Roboz, MD, all of Weill Cornell Medicine, New York City. The 2023 educational program focuses on emerging science; rare diseases and aggressive lymphomas; biology and pathology for clinicians; treatment options and evolving treatments; and more.

There will be a learning track specifically for nurse practitioners and physician assistants, and a Spanish-language session on myeloma will be held on Saturday, October 21. Featured topics in multiple myeloma presented on October 20 include biology and pathology for clinicians, upfront treatment of myeloma, evolving treatment in myeloma, and treatment options in relapsed/refractory multiple myeloma.

The LL&M educational program features four days of comprehensive learning presented by more than 60 faculty experts, and participants can receive up to 25 CME/CE credits. The live event is designed to meet the educational needs of those who are involved or interested in the treatment of patients with hematologic malignancies, including hematologists, medical oncologists, physicians, physician assistants, oncology nurses, nurse practitioners, and pharmacists.

For more information or to register, visit lymphomaandmyeloma.oncnet.com.

ABOUT HMP GLOBAL 

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

ABOUT IMF

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global organization focusing specifically on multiple myeloma. The IMF’s research extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life for myeloma patients while working toward prevention and a cure through four founding principles: Research, Education, Support, and Advocacy. For more information, visit myeloma.org.

Share article on social media or email:

LevinPro HC

“Despite rising labor costs and interest rates, investment activity in physician groups remains strong, especially from private equity buyers and their platforms. A highly fragmented physician market and steady cash flows seem to be enough for investors to push through tough economic conditions.”

NEW CANAAN, Conn. (PRWEB)
July 18, 2023

M&A activity in the Physician Medical Group (PMG) sector increased in Q2:23, reaching a total of 148 transactions, according to data captured in the LevinPro HC database and published by Irving Levin Associates, LLC. Activity in Q2:23 marks a 6% increase from Q1:23 when 139 acquisitions were reported but matches data from Q2:22 when 147 deals were announced.

Private equity firms and their sponsored platforms remain the most active investors in the market, accounting for 62% of all announced transactions. PE firms targeted dental practices in more than a third of the transactions, making them the hottest vertical in the physician market, followed by eyecare providers. MB2 Dental Solutions, a portfolio company of Charlesbank Capital Partners, played an outsized role in the deal volume, announcing 22 transactions in Q2 alone. The PE-backed company is one of the leading dental services organizations in the country and has been one of the major players in the market for the past several years.

The largest physician deal, by disclosed price at least, was the acquisition of OneOncology Inc. by TPG Capital and AmerisourceBergen valued at $2.1 billion. AmerisourceBergen is only a minority investor in this transaction, buying a 35% ownership stake valued at $685 million in cash.

“Despite rising labor costs and interest rates, investment activity in physician groups remains strong, especially from private equity buyers and their platforms” stated Dylan Sammut, Editor of Healthcare at Irving Levin Associates, LLC. “A highly fragmented physician market and steady cash flows seem to be enough for investors to push through tough economic conditions.”

Health systems were also in the market for physician groups, announcing 10 acquisitions to expand their outpatient care networks. Practices focused on women’s health were a major draw for large health systems like Augusta Health and Mercy Iowa City, primarily driven by demographic trends, expanded coverage from insurance providers and new social-cultural dynamics in the country.

“Dental and eyecare practices have always seen high investor demand, but keep an eye out for previously overlooked verticals, such as women’s health providers and OB/GYN clinics,” continued Sammut. “That’s a very fragmented market and demand is outpacing the supply of clinicians. Investors would be smart to capitalize on these new tailwinds.”

All quarterly results are published in The Health Care M&A Report, which is part of LevinPro HC, a research intelligence platform published by Irving Levin Associates, LLC. For information, or to order the reports, call 800-248-1668. Irving Levin Associates is celebrating more than 70 years of delivering exclusive M&A intelligence to its sophisticated audience of seniors housing and healthcare investors. The company was established in 1948 and has offices in New Canaan, Connecticut and North Bethesda, Maryland. The company publishes research reports and newsletters and maintains databases on the healthcare and senior housing M&A markets.

Share article on social media or email:

Book Cover

“With Dementia seen as a particularly unknown disease that can come on at any point in anyone’s life and affect the individual and their loved ones,” Sayers said. “I hope my wisdom, practical experience, and faith help readers find solace in my words.”

WATERDOWN, Ontario (PRWEB)
July 17, 2023

Author Margaret Sayers welcomes readers into the world of dementia and caring for those afflicted with the disease while sharing her helpful tips intertwined with faith in her new book, “Lest We Forget.”

The book aims to lend a helping hand through word by sharing Sayers’ personal and faith-based experiences in healthcare, specifically dealing with those who have been diagnosed with dementia coupled with those caring for them.

Sayers gives a rendition of how this book came about, stating, “I was a “friendly visitor” to a saintly lady from my church. Her dementia worsened, and she was moved into a nursing home,” Sayers said. “As she declined further, she was no longer comforted by familiar scriptures but rather was tormented by scriptures that spoke of sin or the unpardonable sin. I understood what was happening clinically and explained her response to the scriptures to her family and visitors. This prompted me to write a book to educate and comfort.”

Educated and having been in the healthcare field for decades, Sayers puts her practical experience in dealing firsthand with dementia patients and their loved ones into words, hoping to guide and shed light for readers during a difficult and tumultuous time.

“With Dementia seen as a particularly unknown disease that can come on at any point in anyone’s life and affect the individual and their loved ones,” Sayers said. “I hope my wisdom, practical experience, and faith help readers find solace in my words and may use my advice that exudes the care I have for dementia patients.”

“Lest We Forget”

By Margaret Sayers

ISBN: 9781664298040 (softcover); 9781664298057 (electronic)

Available at WestBow Press, Amazon and Barnes & Noble

About the author

Margaret is a retired Nurse Practitioner with over 50 years of experience caring for older adults with multiple chronic illnesses, including dementia. Her clinical training was done at Upstate Medical Center in Syracuse, N.Y. In addition, she obtained a graduate degree in Epidemiology at the University of Buffalo. To learn more, please visit http://www.margaretsayers.com.

General Inquiries:            

LAVIDGE – Phoenix                        

Taylor Moralez

tmoralez@lavidge.com

Share article on social media or email:

To provide access to the data used to create the new AI model, the researchers developed a website that enables users to explore relationships between genes, drugs, and birth defects.

NEW YORK (PRWEB)
July 17, 2023

Data scientists at the Icahn School of Medicine at Mount Sinai in New York and colleagues have created an artificial intelligence model that may more accurately predict which existing medicines, not currently classified as harmful, may in fact lead to congenital disabilities.

The model, or “knowledge graph,” described in the July 17 issue of the Nature journal Communications Medicine [DOI: 10.1038/s43856-023-00329-2], also has the potential to predict the involvement of pre-clinical compounds that may harm the developing fetus. The study is the first known of its kind to use knowledge graphs to integrate various data types to investigate the causes of congenital disabilities.

Birth defects are abnormalities that affect about 1 in 33 births in the United States. They can be functional or structural and are believed to result from various factors, including genetics. However, the causes of most of these disabilities remain unknown. Certain substances found in medicines, cosmetics, food, and environmental pollutants can potentially lead to birth defects if exposed during pregnancy.

“We wanted to improve our understanding of reproductive health and fetal development, and importantly, warn about the potential of new drugs to cause birth defects before these drugs are widely marketed and distributed,” says Avi Ma’ayan, PhD, Professor, Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics at Icahn Mount Sinai, and senior author of the paper. “Although identifying the underlying causes is a complicated task, we offer hope that through complex data analysis like this that integrates evidence from multiple sources, we will be able, in some cases, to better predict, regulate, and protect against the significant harm that congenital disabilities could cause.”

The researchers gathered knowledge across several datasets on birth-defect associations noted in published work, including those produced by NIH Common Fund programs, to demonstrate how integrating data from these resources can lead to synergistic discoveries. Particularly, the combined data is from the known genetics of reproductive health, classification of medicines based on their risk during pregnancy, and how drugs and pre-clinical compounds affect the biological mechanisms inside human cells.

Specifically, the data included studies on genetic associations, drug- and preclinical-compound-induced gene expression changes in cell lines, known drug targets, genetic burden scores for human genes, and placental crossing scores for small molecule drugs.

Importantly, using ReproTox-KG, with semi-supervised learning (SSL), the research team prioritized 30,000 preclinical small molecule drugs for their potential to cross the placenta and induce birth defects. SSL is a branch of machine learning that uses a small amount of labeled data to guide predictions for much larger unlabeled data. In addition, by analyzing the topology of the ReproTox-KG more than 500 birth-defect/gene/drug cliques were identified that could explain molecular mechanisms that underlie drug-induced birth defects. In graph theory terms, cliques are subsets of a graph where all the nodes in the clique are directly connected to all other nodes in the clique.

Share article on social media or email: